A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)
Status:
Not yet recruiting
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
This purpose of this study is to compare the pharmacokinetics (PK) of a single dose of
MK-0616 in participants with moderate renal impairment (RI) to those of healthy matched
control participants. This study is being conducted to assess the impact of moderate renal
insufficiency on the PK of MK-0616.